595 - Olorofim (OLO) for treatment of invasive mould infections in patients with limited or no treatment options: PK data from a Phase 2b open-label study (NCT03583164, Study 32)

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

JW

James G. Wright, PhD

Director
Wright Dose Ltd
Altrincham, England, United Kingdom
AC

Andrew Cristinacce, MSc by Research

Wright Dose Ltd
Altrincham, England, United Kingdom
HG

Hal Galbraith, PharmD

Senior Director, Clinical Pharmacology
IQVIA
Lees Summit, Missouri, United States
RB

Roger Bruggemann, Pharm, PhD

PharmD, PhD
Radboud university medical centre
Nijmegen, Gelderland, Netherlands
Johan A. Maertens, MD PhD

Professor
KU Leuven
Leuven, Brussels Hoofdstedelijk Gewest, Belgium
George R. Thompson, III, MD

Professor
University of California Davis Medical Center
Sacramento, California, United States
SC

Sharon C. Chen, PhD MBBS

Professor
Westmead Hospital
Sydney, New South Wales, Australia
John H. Rex, MD

Chief Medical Officer
F2G, Limited
WELLESLEY HILLS, MA, United States